Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Notes Payables: 2011-2025

Historic Notes Payables for Heron Therapeutics (HRTX) over the last 7 years, with Jun 2025 value amounting to $149.8 million.

  • Heron Therapeutics' Notes Payables was N/A to $149.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $149.8 million, marking a year-over-year change of. This contributed to the annual value of $7.1 million for FY2020, which is 25.41% up from last year.
  • As of Q2 2025, Heron Therapeutics' Notes Payables stood at $149.8 million, which was up 1,882.87% from $7.6 million recorded in Q1 2021.
  • In the past 5 years, Heron Therapeutics' Notes Payables ranged from a high of $149.8 million in Q2 2025 and a low of $7.6 million during Q1 2021.
  • Moreover, its 1-year median value for Notes Payables was $149.8 million (2025), whereas its average is $149.8 million.
  • Data for Heron Therapeutics' Notes Payables shows a peak YoY increased of 27.32% (in 2021) over the last 5 years.
  • Over the past 2 years, Heron Therapeutics' Notes Payables (Quarterly) stood at $7.6 million in 2021, then followed by $149.8 million in 2025.
  • Its Notes Payables stands at $149.8 million for Q2 2025, versus $7.6 million for Q1 2021 and $7.1 million for Q4 2020.